InvestLog
Back to Market返回行情

PLRZ Polyrizon Ltd.

USHealthcare
$14.65+2.02%ClosedMarket Cap: $16.4M

As of 2026-07-10 16:00

Why PLRZ matters now

Polyrizon Ltd. (PLRZ) is a US stock in Healthcare. The latest InvestLog snapshot shows $14.65 with +2.02% on the session and $16.4M in market capitalization; recent performance reads 1-month -4.01% and YTD +58.07%.

The latest financial table shown here is Q4 2025, with revenue of $0.00, net income of $-3.2M, and EPS of $-1.96. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -23.4%.

The latest indexable market news headline is "Polyrizon Announces Successful Results for NASARIX™ Biocompatibility Program, Supporting Advancement Towards First in Human Clinical Trial" from GlobeNewsWire.

Additional event context on this page matters because recent insider activity includes Adler Oz filing S-Sale. These signals are research inputs, not a recommendation.

Valuation

P/E (TTM)

—

PEG

—

P/B

1.03

P/S

0.00

EV/EBITDA

-3.08

DCF Value

$0.81

FCF Yield

-23.4%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-26.1%

ROA

-19.2%

ROIC

-17.9%

Financials

PeriodRevenueNet IncomeEPS
Q4 2025$0.00$-3.2M$-1.96
FY 2025$0.00$-3.3M$-2.07
Q2 2025$0.00$-88.50$-0.06
Q1 2025$0.00$-88.50$-0.06

Trading Activity

Insider Trades

Adler Ozdirector
Sell2026-04-01
Carmel Lirondirector
Sell2026-04-01
Izraeli Tomerdirector, officer: Chief Executive Officer
Sell2026-04-01
Turgeman Tidhardirector, officer: Chief Technology Officer
Sell2026-03-31
Izraeli Tomerdirector, officer: Chief Executive Officer
Sell2026-03-31

Related Stocks

AIM
AIM ImmunoTech Inc.
$1.3M
CYCN
Cyclerion Therapeutics, Inc.
$13.8M
KTTA
Pasithea Therapeutics Corp.
$4.2M
NBY
NovaBay Pharmaceuticals, Inc.
$39.1M
PMCB
PharmaCyte Biotech, Inc.
$5.5M

Latest News

Polyrizon Announces Successful Results for NASARIX™ Biocompatibility Program, Supporting Advancement Towards First in Human Clinical TrialGlobeNewsWire · 2026-07-02
Polyrizon Makes Strong Progress: Receives Central IRB Approval for its Allergy Blocker Clinical TrialGlobeNewsWire · 2026-06-29
Polyrizon Receives Notice of U.S. Patent Publication for Mucoadhesive Drug Delivery PlatformGlobeNewsWire · 2026-06-17
Polyrizon Advances NASARIX™ Development with Key Human Study to Characterize Nasal Residence Time and Support FDA Regulatory PathwayGlobeNewsWire · 2026-06-15
Polyrizon Receives Notice of European Patent Publication for Innovative Mucoadhesive Nasal Drug Delivery TechnologyGlobeNewsWire · 2026-06-10

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

IL

Exchange

—

Beta

-1.84

Polyrizon Ltd. is an Israeli biotechnology firm specializing in the creation of medical device hydrogels, delivered as nasal sprays. These innovative sprays are designed to form a protective barrier within the nasal cavity, preventing viruses and allergens from attaching to the nasal epithelial tissue. Its current development pipeline features several targeted solutions, including PL-14, formulated to block nasal allergies; PL-15, aimed at combating COVID-19; and PL-16, for influenza prevention. Established in 2005, the company operates from its headquarters in Ra'anana, Israel.